Akzo Nobel’s healthcare business, Organon, drew a line under its long-running patent litigation suit with Barr subsidiary Duramed Pharmaceuticals for a generic version of its contraceptive Mircette (desogestrel/ethinyl estradiol) yesterday.
The company agreed a settlement with Barr in which the US generics house will pay Organon $139 million dollars to settle the litigation and to acquire all rights relating to Mircette, including the US marketing approval.
Patent litigation between the companies was put on hold in September, when the first details of the deal were announced, to allow all parties involved to negotiate the settlement agreement. Barr markets a generic version of Mircette under the trade name Kariva.
